Misuse of the unspecified coccidioidomycosis diagnosis code: An audit of electronic health records.

IF 2.3 3区 医学 Q3 INFECTIOUS DISEASES
Craig I Coleman, Sherry Danese, Julie Ulloa, Mark Bresnik, Belinda Lovelace, Fariba Donovan
{"title":"Misuse of the unspecified coccidioidomycosis diagnosis code: An audit of electronic health records.","authors":"Craig I Coleman, Sherry Danese, Julie Ulloa, Mark Bresnik, Belinda Lovelace, Fariba Donovan","doi":"10.1093/mmy/myaf091","DOIUrl":null,"url":null,"abstract":"<p><p>Widespread use of the 'unspecified coccidioidomycosis' code (B38.9) may negatively impact provider reimbursement and complicate study of disease burden. We sought to determine the frequency of B38.9 use in routine practice and assess how often it could be changed to a more specific code, what code that might be, and reasons for its initial use. To estimate the proportion of all coccidioidomycosis cases that were classified using the International Classification of Diseases-Tenth-Revision unspecified diagnosis code (B38.9), three real-world datasets were queried. Further, in January 2025, providers in coccidioidomycosis-endemic areas were invited to participate in an online electronic health record (EHR) audit to study their three most recent patients coded as B38.9 over the prior 12 months. The proportion of patients that could have received a more specific coccidioidomycosis code by provider was determined, as were the recommended alternative code(s), and reasons for the B38.9's initial use. Across queried datasets, 17.8-49.5% of coccidioidomycosis cases were coded as unspecified. We recruited 19 providers to audit EHRs of 53 patients, in which B38.9 was used. Thirty-six (67.9%) patients could have been assigned a more specific coccidioidomycosis code, including 14 (38.9%) to disseminated disease (B38.7). Common reasons for using B38.9 included evolving clinical assessment (37.0%), lack of coding expertise (22.2%), and entry errors (22.2%). In conclusion, a substantial proportion of coccidioidomycosis diagnoses are assigned to B38.9. Over two-thirds of these could have been better described using a more specific code. There is a need for educational efforts to promote more precise coding.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myaf091","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Widespread use of the 'unspecified coccidioidomycosis' code (B38.9) may negatively impact provider reimbursement and complicate study of disease burden. We sought to determine the frequency of B38.9 use in routine practice and assess how often it could be changed to a more specific code, what code that might be, and reasons for its initial use. To estimate the proportion of all coccidioidomycosis cases that were classified using the International Classification of Diseases-Tenth-Revision unspecified diagnosis code (B38.9), three real-world datasets were queried. Further, in January 2025, providers in coccidioidomycosis-endemic areas were invited to participate in an online electronic health record (EHR) audit to study their three most recent patients coded as B38.9 over the prior 12 months. The proportion of patients that could have received a more specific coccidioidomycosis code by provider was determined, as were the recommended alternative code(s), and reasons for the B38.9's initial use. Across queried datasets, 17.8-49.5% of coccidioidomycosis cases were coded as unspecified. We recruited 19 providers to audit EHRs of 53 patients, in which B38.9 was used. Thirty-six (67.9%) patients could have been assigned a more specific coccidioidomycosis code, including 14 (38.9%) to disseminated disease (B38.7). Common reasons for using B38.9 included evolving clinical assessment (37.0%), lack of coding expertise (22.2%), and entry errors (22.2%). In conclusion, a substantial proportion of coccidioidomycosis diagnoses are assigned to B38.9. Over two-thirds of these could have been better described using a more specific code. There is a need for educational efforts to promote more precise coding.

误用未指定球孢子菌病诊断代码:电子健康记录审计。
广泛使用“未指明球孢子菌病”代码(B38.9)可能会对提供者报销产生负面影响,并使疾病负担研究复杂化。我们试图确定B38.9在日常实践中的使用频率,并评估它可以更改为更具体代码的频率,可能是什么代码,以及最初使用它的原因。为了估计使用国际疾病分类第十版未明确诊断代码(B38.9)分类的所有球孢子菌病病例的比例,查询了三个真实世界的数据集。此外,在2025年1月,球孢子菌病流行地区的供应商被邀请参加在线电子健康记录(EHR)审计,以研究他们在过去12个月内编码为B38.9的最近三名患者。确定了可以接受由提供者提供的更具体的球孢子菌病代码的患者比例,以及推荐的替代代码和B38.9最初使用的原因。在查询的数据集中,17.8-49.5%的球孢子菌病病例被编码为未指定。我们招募了19名医疗服务提供者对53名患者的电子病历进行审计,其中使用了B38.9。36例(67.9%)患者可以被分配更具体的球孢子菌病代码,其中14例(38.9%)为播散性疾病(B38.7)。使用B38.9的常见原因包括不断发展的临床评估(37.0%)、缺乏编码专业知识(22.2%)和输入错误(22.2%)。总之,相当大比例的球孢子菌病诊断归属于B38.9。其中三分之二以上可以用更具体的代码来更好地描述。有必要通过教育努力来促进更精确的编码。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical mycology
Medical mycology 医学-兽医学
CiteScore
5.70
自引率
3.40%
发文量
632
审稿时长
12 months
期刊介绍: Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信